Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including Kevetrin, an anti-cancer compound that has completed Phase I clinical trial; and Prurisol, an anti-psoriasis drug candidate that is in Phase II clinical trial. It also focuses on the development of Brilacidin, an antibiotic candidate for the treatment of acute bacterial skin and skin structure infection, oral mucositis, and inflammatory bowel disease, and ulcerative proctitis/colitis; and defensin-mimetics for otic infections, diabetic foot infections, and hidradenitis suppurativa indications.
Type
Public
HQ
Beverly, US
Founded
2007
Size (employees)
15 (est)
Innovation Pharmaceuticals was founded in 2007 and is headquartered in Beverly, US
Report incorrect company information

Key People/Management at Innovation Pharmaceuticals

Leo Ehrlich

Leo Ehrlich

CEO
Arthur Bertolino

Arthur Bertolino

President

Innovation Pharmaceuticals Office Locations

Innovation Pharmaceuticals has an office in Beverly
Beverly, US (HQ)
151 100 Cummings Center
Show all (1)
Report incorrect company information

Innovation Pharmaceuticals Financials and Metrics

Innovation Pharmaceuticals Financials

USD

Net income (Q3, 2018)

(11.5 m)

EBIT (Q3, 2018)

(11.4 m)

Market capitalization (31-Oct-2017)

103.4 m

Closing share price (31-Oct-2017)

0.8

Cash (31-Mar-2018)

1.3 m
Innovation Pharmaceuticals's current market capitalization is $103.4 m.
Annual
USDFY, 2016

General and administrative expense

1.9 m

R&D expense

9 m

Operating expense total

10.9 m

EBIT

(12.7 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

General and administrative expense

244 k275 k339 k352 k249 k362 k344 k331 k889 k

R&D expense

1.9 m2.3 m1.8 m2.1 m3 m2.3 m2.7 m3.2 m9.5 m

Operating expense total

2.2 m2.6 m2.2 m2.5 m3.3 m2.6 m3 m3.5 m11.4 m

EBIT

(2.7 m)(2.8 m)(2.5 m)(3.3 m)(3.7 m)(3 m)(3.3 m)(3.9 m)(11.4 m)
Annual
USDFY, 2016

Cash

6.3 m

Current Assets

6.7 m

Total Assets

11.4 m

Accounts Payable

42.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2018

Cash

7.1 m9.5 m10.8 m7.8 m6.2 m5.3 m1.3 m

Current Assets

7.2 m9.6 m11.4 m8 m6.4 m5.8 m1.5 m

Total Assets

12.5 m14.9 m17.1 m13.5 m11.9 m11.3 m5.8 m

Current Liabilities

8 m7.7 m7.3 m7.5 m7.6 m8.4 m9.5 m
Annual
USDFY, 2016

Net Income

(12.9 m)

Accounts Payable

1.7 m

Cash From Operating Activities

(9.9 m)

Purchases of PP&E

(68 k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(2.8 m)(2.9 m)(2.6 m)(3.3 m)(3.7 m)(3 m)(3.4 m)(3.9 m)
USDY, 2018

Financial Leverage

-1.5 x
Show all financial metrics
Report incorrect company information

Innovation Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information